Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2021 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2021, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
31-03-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and nine months ended December 31, 2020. The advertisements as appeared today i.e. February 11, 2021 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements
11-02-2021

Earnings Call for Q3FY21 of Suven Pharmaceuticals

 Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.
11-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find attached SUVEN PHARMA Q3 FY21 Earnings Presentation
11-02-2021

Suven Pharma Standalone December 2020 Net Sales at Rs 274.93 crore, up 53.85% Y-o-Y

 NULL
10-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting

 With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. February 10, 2021, approved the following along with other business matters. 1. Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and nine months ended 31st December, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors. 2. Interim Dividend a) The Board has also declared an interim dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021. b) The Board approved the Record Date i.e., 18th February, 2021 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. c) The above said dividend will be paid on or before 11th March, 2021
10-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Corporate Action-Board approves Dividend

 Interim Dividend a) The Board has also declared an interim dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021. b) The Board approved the Record Date i.e., 18th February, 2021 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. c) The above said dividend will be paid on or before 11th March, 2021
10-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Took On Record And Approved The Attached Un-Audited Standalone And Consolidated Financial Results Prepared Under Ind AS For The Quarter And Nine Months Ended 31St December, 2020 Pursuant To Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Along With Limited Review Reports Of The Statutory Auditors And Interim Dividend

 With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. February 10, 2021, approved the following along with other business matters. 1. Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and nine months ended 31st December, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors. 2. Interim Dividend a) The Board has also declared an interim dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021. b) The Board approved the Record Date i.e., 18th February, 2021 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. c) The above said dividend will be paid on or before 11th March, 2021
10-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated February 3, 2021 regarding to Notice of Board Meeting, please find enclosed the copies of the newspaper advertisements as appeared today i.e. February 4, 2021 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements
04-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Thursday, February 11, 2021 at 12:00 Noon IST to discuss the Un-audited Financial Results for the Q3 & 9M Financial Year 2021, to be declared on February 10, 2021.
04-02-2021
Next Page
Close

Let's Open Free Demat Account